RE:RE:RE:With over 200 people...Smithwicks wrote: Please go away again as no one cares when you bought and when you sold or any of your bs reasons to scare investors from buying shares in a recession proof company. If you want high flying news releases so you can trade back and forth then this stock isn't for you. Growing revenue is what Arun wants to be judged on. Management receives incentives so if Vanc is cheap Jan 1 and exits next Xmas significantly higher there will be happy investors as well as rewards for management. More OTC products are right behind this one as well. Preferred supplier to LD is worth far more than .28 plus all the chains coming in Jan . Only a few molecules in one chain with recurring orders will create millions of revenue. Go away loser
I know your a long investor M. Smithwick, too bad it has gone under .30 but you know like me that when NPH had good news about 39 molecules, 52 molecules, they were posting it right away 10,12 months ago. Since Nayar exercised is .13 warrants (about a million) and sold them at .60 or so, there has been no significant NR. Sorry, there was one. M. Pirooz has left the boat. You know just like me that every time there's a non significant NR, this become the day flipper paradise for some day, before reaching new low. It won't stop buddy. If NPH had significant news, they would not wait to see it go so low. Tell me this Smith: How come it takes years to be approved for generics by health Canada, that it cost about 300K per generics normally ($10 millions in NPH case) and NPH was able to do it with less then half a million and less then a year? I've call health Canada at the time, I was really suspicious about the 40+ generics, but it was all true. The lady even told me that it cost $300K for each generics normally. That it also cost $300K for natural product, that are not even drugs. So, if NPH was able to get these approval in no time, that a lot of province has put a lot of their generics on their Public Health Plan, how come they can't come out with a NR about the number of pharma they're in? Answer this too; with all the molecules they have in their portfolio, this company should already be over a buck, no? If the insiders were waiting to sell it a $100 millions to a big player, they would act exactly that way, keeping the numbers for themselves, no?